Literature DB >> 11261427

Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency.

F Scaglia1, Y Wang, R H Singh, P P Dembure, M Pasquali, P M Fernhoff, N Longo.   

Abstract

PURPOSE: Primary carnitine deficiency is an autosomal recessive disorder caused by defective carnitine transport and manifests as nonketotic hypoglycemia or skeletal or heart myopathy.
METHODS: To define the mechanisms producing partially reduced plasma carnitine levels in the parents of affected patients, we examined carnitine transport in vivo and in the fibroblasts of a new patient and his heterozygous parents.
RESULTS: Kinetic analysis of carnitine transport in fibroblasts revealed an absence of saturable carnitine transport in the proband's cells and a partially impaired carnitine transport in fibroblasts from both parents, whose cells retained normal Km values toward carnitine (6-9 microM) but reduced Vmax. At steady state, normal fibroblasts accumulated carnitine to a concentration that was up to 80 times the extracellular value (0.5 microM). By contrast, cells from the proband had minimal carnitine accumulation, and cells from both parents had intermediate values of carnitine accumulation. Plasma carnitine levels were slightly below normal in both heterozygous, yet clinically normal, parents and in the paternal grandfather and the maternal grandmother. To define the mechanism producing partially decreased carnitine levels, we studied urinary carnitine losses in heterozygous parents compared with controls. Urinary losses increased linearly (P < 0.05) with plasma carnitine levels in normal controls. When urinary carnitine losses were normalized to plasma carnitine levels, a significant difference was observed between controls and heterozygous individuals (P < 0.01).
CONCLUSIONS: These results indicate that fibroblasts from heterozygotes for primary carnitine deficiency have a decreased capacity to accumulate carnitine and that heterozygotes have increased urinary losses, which may contribute to their reduced plasma carnitine levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11261427     DOI: 10.1097/00125817-199811000-00008

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  25 in total

1.  Carnitine levels in skeletal muscle, blood, and urine in patients with primary carnitine deficiency during intermission of L-carnitine supplementation.

Authors:  J Rasmussen; J A Thomsen; J H Olesen; T M Lund; M Mohr; J Clementsen; O W Nielsen; A M Lund
Journal:  JIMD Rep       Date:  2015-02-10

Review 2.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 3.  Lipid storage myopathy.

Authors:  Wen-Chen Liang; Ichizo Nishino
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

4.  Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.

Authors:  Jan Rasmussen; Olav W Nielsen; Nils Janzen; Morten Duno; Hannes Gislason; Lars Køber; Ulrike Steuerwald; Allan M Lund
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

5.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency.

Authors:  M Kilic; R K Ozgül; T Coşkun; D Yücel; M Karaca; H S Sivri; A Tokatli; M Sahin; T Karagöz; A Dursun
Journal:  JIMD Rep       Date:  2011-09-22

6.  Inhibition of OCTN2-mediated transport of carnitine by etoposide.

Authors:  Chaoxin Hu; Cynthia S Lancaster; Zhili Zuo; Shuiying Hu; Zhaoyuan Chen; Jeffrey E Rubnitz; Sharyn D Baker; Alex Sparreboom
Journal:  Mol Cancer Ther       Date:  2012-03-02       Impact factor: 6.261

7.  Functional and molecular studies in primary carnitine deficiency.

Authors:  Marta Frigeni; Bijina Balakrishnan; Xue Yin; Fernanda R O Calderon; Rong Mao; Marzia Pasquali; Nicola Longo
Journal:  Hum Mutat       Date:  2017-09-14       Impact factor: 4.878

8.  Slc22a5 haploinsufficiency does not aggravate the phenotype of the long-chain acyl-CoA dehydrogenase KO mouse.

Authors:  Pablo Ranea-Robles; Chunli Yu; Naomi van Vlies; Frédéric M Vaz; Sander M Houten
Journal:  J Inherit Metab Dis       Date:  2019-12-23       Impact factor: 4.982

9.  Plasma carnitine ester profile in homozygous and heterozygous OCTN2 deficiency.

Authors:  K Komlósi; L Magyari; G C Talián; E Nemes; R Káposzta; G Mogyorósy; K Méhes; B Melegh
Journal:  J Inherit Metab Dis       Date:  2009-02-24       Impact factor: 4.982

10.  Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screening.

Authors:  Jan Rasmussen; Lars Køber; Allan M Lund; Olav W Nielsen
Journal:  J Inherit Metab Dis       Date:  2013-08-21       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.